Biotechnology

enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24

May 1, 2025 8:05 AM

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today reported financial results for the first quarter 2025. Robert Berman, enVVeno Medical's Chief Executive Officer, commented "In the first quarter, we continued to present our compelling 1-year data from the U.S. pivotal trial at leading global, scientific conferences to socialize and...

Read more

Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences

May 1, 2025 8:01 AM

Tharimmune, Inc., (Nasdaq:THAR) ("Tharimmune" or the "Company") a clinical-stage biopharmaceutical company focused on developing innovative therapeutics in inflammation & immunology announced abstracts featuring clinical data on its lead drug candidate, TH104, have been accepted for presentation at the Digestive Disease Week (DDW) Annual Meeting and at the European Association for the Study of the Liver (EASL) International Liver Congress. Both...

Read more

Aspira Reaches Another ARPA-H Milestone, Eligible to Receive Additional $1.5 Million in Second Quarter

May 1, 2025 7:00 AM

Aspira Women's Health Inc. ("Aspira") (OTC PINK:AWHL), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the successful submission of its third development milestone of its Advanced Research Projects Agency for Health (ARPA-H) award. The third milestone focused heavily on additional analytical development steps. The milestone specifically required the completion of...

Read more

A Co-Founder of Athos Therapeutics, Dr. Michael E. Jung, Wins the National Academy of Sciences Award for Chemistry in Service to Society

April 30, 2025 11:30 AM

Athos Therapeutics, Inc. ("Athos"), a clinical stage biotechnology company pioneering the development of precision small molecule therapeutics for patients with immune-mediated diseases, is honored to announce that Dr. Michael E. Jung, a co-founder of Athos, was awarded the National Academy of Sciences Award for Chemistry in Service to Society. This highly prestigious award recognizes "the profound benefits of chemistry to society and how...

Read more

Change in Number of Shares and Votes in Alligator Bioscience AB

April 30, 2025 9:15 AM

During April 2025, the number of shares and votes in Alligator Bioscience AB (STO:ATORX) ("Alligator Bioscience") has decreased as a result of the redemption of all 779,169 outstanding series C shares, as well as the reverse split of ordinary shares, which were resolved by the extraordinary general meeting on 27 March 2025. As of 30 April 2025, the total number of shares and votes in Alligator Bioscience amounts to 16,905,477, of which all...

Read more

Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors

April 30, 2025 8:01 AM

Tharimmune, Inc., (NASDAQ:THAR) ("Tharimmune" or the "Company") a clinical-stage biopharmaceutical company focused on developing innovative therapeutics in inflammation & immunology, today announced the appointment of Clay Kahler and Gary Stetz to its Board of Directors, increasing the Tharimmune Board to nine Directors. As reported in a Form 8-K filed on April 25, 2025, Directors Leonard Mazur and Lynne Bui, M.D. have notified the Board that...

Read more

Resolutions at BioInvent's Annual General Meeting 2025

April 29, 2025 11:15 AM

The Annual General Meeting ("AGM") of BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) resolved to re-elect the Board members Natalie Berner, Kristoffer Bissessar, Thomas Hecht, Leonard Kruimer, Laura Lassouw-Polman, Nanna Lüneborg, Vincent Ossipow and Bernd Seizinger and to implement a long-term incentive program. The AGM voted in favor of adopting the income statements and balance sheets for the Group and the parent company for...

Read more

Jord BioScience Field Trials Deliver Breakthrough Consistency in Biological Crop Protection, Boosting Soybean Yields Across Midwest

April 29, 2025 10:00 AM

Jord BioScience, a leading science and analytics company providing customizable microbial solutions for agriculture, unveiled two years of field trial data showing its proprietary microbial solutions consistently outperform industry-standard treatments, increasing soybean yield by up to 3.1 bushels per acre across 16 Midwest locations-even under dramatically different weather conditions. The company's approach, powered by its 6,500-isolate...

Read more

Petros Proprietary Technology Platform Aligns with April 15, 2025 President Trump Executive Order Advancing Rx-to-OTC Reclassification Reforms

April 29, 2025 9:20 AM

Petros Pharmaceuticals, Inc. (Nasdaq:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over the counter ("OTC") drug development programs, today highlights President Trump's April 15, 2025 Executive Order, titled, "Lowering Drug Prices By Once Again Putting Americans First" (the "Executive Order"), as a demonstration that the Company's recent strategic shift is well timed to the current...

Read more

Scipher Medicine and InnoSIGN Announce Partnership to Advance Precision Medicine in Immunology

April 29, 2025 9:00 AM

InnoSIGN, a company focused on industrializing RNAseq data through its proprietary signaling pathway technology and Scipher Medicine, a leading network biology, AI-data driven therapeutics company, today announced a strategic partnership aimed at advancing the understanding and treatment of complex immune-mediated diseases. The collaboration will leverage Scipher Medicine's unique RNA sequencing data from patients with autoimmune, inflammatory...

Read more

BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Cutaneous T-cell Lymphoma

April 29, 2025 6:15 AM

BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to BI-1808, a first-in-class anti-TNFR2 antibody, for the treatment of adults with relapsed or refractory mycosis fungoides and Sézary...

Read more

BioInvent International AB: Interim Report January - March 2025

April 29, 2025 2:20 AM

BioInvent International (STO:BINV) "The first quarter of 2025 was a highly productive period across clinical development, regulatory milestones, and strategic partnerships - positioning us for strong momentum through the remainder of the year."- Martin Welschof CEO of BioInvent. EVENTS IN THE FIRST QUARTER (R) Positive initial efficacy data from Phase 2a trial of triple combination of the company's lead anti-FcyRIIB antibody BI-1206, rituximab...

Read more

Exercise Price Determined for the Exercise of Warrants Series TO 12 in Alligator Bioscience AB

April 28, 2025 2:30 PM

Alligator Bioscience (STO:ATORX) Alligator Bioscience AB ("Alligator Bioscience" or the "Company") hereby announces that the exercise price for warrants series TO 12 (the "warrants") has been determined to SEK 3.68. The exercise period for the warrants commences on 5 May 2025 and runs up to and including 19 May 2025. The last day of trading in the warrants is 15 May 2025. Alligator Bioscience carried out a rights issue of units during December...

Read more

Data4Cure Presents Advances in AI-Driven Drug Target Discovery and Cancer Subtyping at AACR 2025

April 28, 2025 10:00 AM

Data4Cure, Inc., a leading biomedical data-to-knowledge company, today announced the presentation of two new research abstracts at the 2025 American Association for Cancer Research (AACR) Annual Meeting. The presentations highlight Data4Cure's advances in AI-based approaches for drug target discovery and large-scale cancer subtyping using foundation models applied to large collections of sequencing data. In the first study, titled "Knowledge...

Read more

Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback

April 28, 2025 8:01 AM

Tharimmune, Inc., (Nasdaq:THAR) ("Tharimmune" or the "Company") a clinical-stage biopharmaceutical company focused on developing innovative therapeutics in inflammation & immunology, recently announced positive feedback from the U.S. Food and Drug Administration (FDA) regarding TH104. The agency confirmed that no additional clinical trials appear to be necessary prior to a 505(b)(2) New Drug Application (NDA) submission. TH104 is a buccal film...

Read more

ClearPoint Neuro, Together with its Partner Clinical Laserthermia Systems, Announces FDA Submission to Expand the Labeling of ClearPoint Prism(R) to Include 1.5 T MRI

April 28, 2025 8:00 AM

ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, announces that today its partner, Clinical Laserthermia Systems AB (publ) (CLS), completed the submission of its 510(k) application to the FDA, expanding the indication of the ClearPoint Prism Neuro Laser Therapy System to include 1.5 T MRI guidance. ClearPoint Prism has already seen...

Read more

ClearPoint Neuro to Announce First Quarter 2025 Results May 13, 2025

April 25, 2025 8:00 AM

ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2025 first quarter on Tuesday, May 13th, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2025 first quarter on Tuesday, May 13th, at 4:30 p.m. Eastern time...

Read more

IGC Pharma Welcomes Strategic Investment from Advisors

April 24, 2025 9:30 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced that the Company's recently appointed advisors entered into a Share Purchase Agreement (the "SPA") on April 21, 2025, for the purchase of common shares from the Company. The investment, subject to the terms and conditions set forth in the SPA, is for approximately $475 thousand at the higher of 30 cents or $0.01 over the last closing price. The completion of the...

Read more

Lung Cancer Drug Candidate Results From Archetype Therapeutics to Be Presented at 2025 AACR Annual Meeting

April 24, 2025 9:00 AM

Archetype Therapeutics, a drug discovery company that uses generative AI to rapidly screen billions of potential drugs virtually for their clinical impact in genomically-defined patient cohorts, announced today an upcoming oral presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30 in Chicago, Illinois. The presentation will showcase in vitro and in vivo (GEMM and xenograft) validation...

Read more

ClearPoint Neuro Announces Full Market Release of ClearPoint Navigation Software Version 3.0 - Delivering the First End-to-End ClearPoint Navigation Solution to the Operating Room

April 24, 2025 8:00 AM

ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced the full market release of the ClearPoint Navigation Software Version 3.0 - which introduces an iCT image-guidance workflow option performed in the traditional operating room. "The new iCT-guided neuro navigation workflow builds on our team's decade of experience with...

Read more